Affordable Access

deepdyve-link
Publisher Website

GLP-1 Analog Modulates Appetite, Taste Preference, Gut Hormones, and Regional Body Fat Stores in Adults with Obesity.

Authors
  • Kadouh, Hoda1
  • Chedid, Victor1
  • Halawi, Houssam1
  • Burton, Duane D1
  • Clark, Matthew M2
  • Khemani, Disha1
  • Vella, Adrian3
  • Acosta, Andres1
  • Camilleri, Michael1
  • 1 Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, US.
  • 2 Department of Psychology, Mayo Clinic, Rochester, MN, US.
  • 3 Division of Endocrinology, Mayo Clinic, Rochester, MN, US.
Type
Published Article
Journal
The Journal of Clinical Endocrinology & Metabolism
Publisher
The Endocrine Society
Publication Date
May 01, 2020
Volume
105
Issue
5
Identifiers
DOI: 10.1210/clinem/dgz140
PMID: 31665455
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Obesity is associated with alterations in appetite, gastrointestinal hormone levels and excessive fat mass. We previously published a double-blind, placebo-controlled, randomized, 16-week trial on effects of once-daily glucagon-like peptide-1 (GLP-1) analog, liraglutide on weight, satiation, and gastric functions in obese volunteers. The aim of this substudy is to compare to placebo the effects of liraglutide on appetite, taste preference, regional body fat stores, and anthropometric measurements. Forty obese adults received standard instruction for weight management, monthly behavioral intervention utilizing motivational interviews, and 16-week treatment of once-daily liraglutide (escalated to 3 mg SQ daily). At baseline and 16 weeks, the following were measured: appetite and taste preferences rated every 30 min for 5 h after ingesting 300 mL Ensure®; maximal tolerated volume (MTV) with a nutrient drink test; fasting and postprandial bioactive GLP-1 (7-36) and peptide YY (PYY) levels; total and regional body fat with dual-energy X-ray absorptiometry, and waist and hip circumference. Thirty-five participants (17 liraglutide; 18 placebo) completed the trial. Compared to placebo group, liraglutide group had significant reductions in MTV; prospective food consumption score; desire to eat something sweet, salty, savory or fatty; and an increase in perceived fullness. Postprandial plasma levels of GLP-1 decreased and PYY levels increased with liraglutide relative to baseline. Significant reductions in total body, trunk, and upper and lower body fat without reduction in lean body mass were observed. Liraglutide 3 mg SQ modulates appetite, taste preference, gut hormones, and regional body fat stores in adults with obesity without reduction in lean body mass. © Endocrine Society 2019. All rights reserved. For permissions, please e-mail: [email protected]

Report this publication

Statistics

Seen <100 times